Oxidative stress in Niemann-Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy

[1]  Mauricio González,et al.  Alteration of Gene Expression Profile in Niemann-Pick Type C Mice Correlates with Tissue Damage and Oxidative Stress , 2011, PloS one.

[2]  A. Sitta,et al.  Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. , 2011, Molecular genetics and metabolism.

[3]  R. Sandhir,et al.  Alterations in Ca²⁺ homeostasis and oxidative damage induced by ethion in erythrocytes of Wistar rats: ameliorative effect of vitamin E. , 2011, Environmental toxicology and pharmacology.

[4]  A. Sitta,et al.  Oxidative Stress in Phenylketonuria: What is the Evidence? , 2011, Cellular and Molecular Neurobiology.

[5]  C. Vite,et al.  Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease , 2010, Science Translational Medicine.

[6]  W. Pavan,et al.  Oxidative stress in Niemann-Pick disease, type C. , 2010, Molecular genetics and metabolism.

[7]  S. Sturley,et al.  Niemann–Pick type C pathogenesis and treatment: from statins to sugars , 2010, Clinical lipidology.

[8]  M. Patterson,et al.  Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. , 2010, Molecular genetics and metabolism.

[9]  J. E. Wraith,et al.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat , 2009, Therapeutics and clinical risk management.

[10]  F. Sedel,et al.  Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. , 2009, Molecular genetics and metabolism.

[11]  R. Roesler,et al.  Alterations in Oxidative Markers in the Cerebellum and Peripheral Organs in MPS I Mice , 2009, Cellular and Molecular Neurobiology.

[12]  A. Colell,et al.  Mitochondrial Cholesterol Loading Exacerbates Amyloid β Peptide-Induced Inflammation and Neurotoxicity , 2009, The Journal of Neuroscience.

[13]  R. Cenedella.  Cholesterol Synthesis Inhibitor U18666A and the Role of Sterol Metabolism and Trafficking in Numerous Pathophysiological Processes , 2009, Lipids.

[14]  A. Galione,et al.  Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium , 2008, Nature Medicine.

[15]  B. Bembi,et al.  Oxidative stress in NPC1 deficient cells: protective effect of allopregnanolone , 2008, Journal of cellular and molecular medicine.

[16]  D. Ory,et al.  Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. , 2008, The Journal of clinical investigation.

[17]  J. Dingemanse,et al.  Influence of Food Intake on the Pharmacokinetics of Miglustat, an Inhibitor of Glucosylceramide Synthase , 2007, Journal of clinical pharmacology.

[18]  M. Patterson,et al.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.

[19]  S. Pfeffer,et al.  Clues to Neuro-Degeneration in Niemann-Pick Type C Disease from Global Gene Expression Profiling , 2006, PloS one.

[20]  A. Sitta,et al.  The effect of Lorenzo's oil on oxidative stress in X-linked adrenoleukodystrophy , 2006, Journal of the Neurological Sciences.

[21]  U. Brunk,et al.  Lysosomal labilization , 2006, IUBMB life.

[22]  Roberto Colombo,et al.  Protein carbonylation, cellular dysfunction, and disease progression , 2006, Journal of cellular and molecular medicine.

[23]  V. D’Almeida,et al.  Blood oxidative stress markers in Gaucher disease patients. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[24]  R. Maue,et al.  Before the loss: neuronal dysfunction in Niemann-Pick Type C disease. , 2004, Biochimica et biophysica acta.

[25]  S. Walkley,et al.  Consequences of NPC1 and NPC2 loss of function in mammalian neurons. , 2004, Biochimica et biophysica acta.

[26]  M. Patterson,et al.  The pathophysiology and mechanisms of NP-C disease. , 2004, Biochimica et biophysica acta.

[27]  M. Wajner,et al.  The role of oxidative damage in the neuropathology of organic acidurias: Insights from animal studies , 2004, Journal of Inherited Metabolic Disease.

[28]  S. Mellon,et al.  Niemann–Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone , 2004, Nature Medicine.

[29]  R. Dwek,et al.  Accumulation of Glycosphingolipids in Niemann-Pick C Disease Disrupts Endosomal Transport* , 2004, Journal of Biological Chemistry.

[30]  Danielle A. Simmons,et al.  Postnatal development of inflammation in a murine model of Niemann–Pick type C disease: immunohistochemical observations of microglia and astroglia , 2003, Experimental Neurology.

[31]  J. Crowley,et al.  NPC1 and NPC2 Regulate Cellular Cholesterol Homeostasis through Generation of Low Density Lipoprotein Cholesterol-derived Oxysterols* , 2003, Journal of Biological Chemistry.

[32]  R. Schiffmann,et al.  Glucosylceramide and Glucosylsphingosine Modulate Calcium Mobilization from Brain Microsomes via Different Mechanisms* , 2003, Journal of Biological Chemistry.

[33]  Roberto Colombo,et al.  Protein carbonyl groups as biomarkers of oxidative stress. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[34]  G. Pastores,et al.  Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1 , 2003, Expert opinion on investigational drugs.

[35]  Hiroyoshi Suzuki,et al.  Pathologic changes of glial cells in murine model of Niemann–Pick disease type C: Immunohistochemical, lectin‐histochemical and ultrastructural observations , 2003, Pediatrics international : official journal of the Japan Pediatric Society.

[36]  C. Scriver.  The Metabolic and Molecular Bases of Inherited Disease , 2001 .

[37]  S. Walkley,et al.  Neurons in Niemann‐Pick Disease Type C Accumulate Gangliosides as Well as Unesterified Cholesterol and Undergo Dendritic and Axonal Alterations , 2001, Journal of neuropathology and experimental neurology.

[38]  B. Halliwell,et al.  Free Radicals and Hearing: Cause, Consequence, and Criteria , 1999, Annals of the New York Academy of Sciences.

[39]  A. Honda,et al.  Cholesterol and oxygenated cholesterol concentrations are markedly elevated in peripheral tissue but not in brain from mice with the Niemann–Pick type C phenotype , 1998, Journal of Inherited Metabolic Disease.

[40]  G. Addison.  The Metabolic and Molecular Bases of Inherited Disease CD-ROM (Version 1.0) Edited by C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle , 1997, Journal of Inherited Metabolic Disease.

[41]  G. Dallner,et al.  Peroxisomal Impairment in Niemann-Pick Type C Disease* , 1997, The Journal of Biological Chemistry.

[42]  C. Rice-Evans,et al.  A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. , 1993, Clinical science.

[43]  L. Liscum,et al.  The intracellular transport of low density lipoprotein-derived cholesterol is defective in Niemann-Pick type C fibroblasts , 1989, The Journal of cell biology.

[44]  B. Halliwell,et al.  Free radicals in biology and medicine , 1985 .

[45]  K. Yagi,et al.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. , 1979, Analytical biochemistry.

[46]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[47]  S. Kothare,et al.  Treatment of cataplexy in Niemann-Pick disease type C with the use of miglustat. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[48]  V. G. Pereira,et al.  Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[49]  R. Proia,et al.  Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. , 2005, Molecular genetics and metabolism.

[50]  R. Artuch,et al.  Lipophilic antioxidants in patients with phenylketonuria. , 2003, The American journal of clinical nutrition.

[51]  R. Giugliani,et al.  Fibroblasts of skin fragments as a tool for the investigation of genetic diseases: technical recommendations , 2000 .

[52]  R. Browne,et al.  Reduced glutathione and glutathione disulfide. , 1998, Methods in molecular biology.

[53]  I. Singh,et al.  Tissue differences in antioxidant enzyme gene expression in response to endotoxin , 1996 .

[54]  S. Ameshima,et al.  [Glutathione peroxidase]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[55]  E. Stadtman,et al.  Determination of carbonyl content in oxidatively modified proteins. , 1990, Methods in enzymology.

[56]  H. Aebi,et al.  Catalase in vitro. , 1984, Methods in enzymology.

[57]  A. Wendel.  [44] Glutathione peroxidase , 1981 .